Enyzme immunoassay compared to immunodiffusion complement-fixation to assess the IgG serological response in coccidioidomycosis.

IF 3.5 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2026-05-01 DOI:10.1093/mmy/myag047

Chinh T Nguyen, Neil M Ampel

引用次数: 0

Abstract

Enzyme immunoassay (EIA) is often the initial test performed for diagnosing coccidioidomycosis by serology. When EIA immunoglobulin G (IgG) optical density (OD) positive results were compared to immunodiffusion complement-fixation (IDCF) titer among 339 unique patient samples, there was only moderate correlation (R2 = 0.5345; P < 0.001). In 68 cases (20.1%), the EIA IgG was positive when the IDCF result was negative. When the medical records of 22 patients at one site were reviewed, only 14 (63.6%) with positive EIA IgG tests were associated with clinically active coccidioidomycosis. These results support not using EIA IgG OD as a substitute for CF titer and that an isolated positive EIA IgG may be falsely positive.

查看原文本刊更多论文

酶免疫测定法与免疫扩散补体固定法比较评价球虫菌病IgG血清学反应。

酶免疫测定（EIA）通常是最初的测试执行球虫真菌病的血清学诊断。将339例特殊患者标本中EIA免疫球蛋白G （IgG）光密度（OD）阳性结果与免疫扩散补体固定（IDCF）滴度进行比较，两者仅存在中度相关性(R2=0.5345

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.